Abstract #1000028: Injection Site Reactions and Their Impact in Patients With Acromegaly Receiving Injectable Somatostatin Receptor Ligands in the Phase 3 MPOWERED Trial

Injectable somatostatin receptor ligands (iSRLs) are used to treat acromegaly. However, injection site reactions (ISRs) are common and impact patient activities of daily living and quality of life (QOL).1-3 Recently, oral octreotide capsules (OOC; MYCAPSSA®) were approved in the United States as a new treatment option for adult patients with acromegaly previously responding to iSRLs (octreotide or lanreotide). MPOWERED is a phase 3 trial...